Prognostic factors in ductal pancreatic cancer

C. J. Yeo, John L Cameron

Research output: Contribution to journalArticle

Abstract

Introduction: The diagnosis of pancreatic adenocarcinoma remains a devastating life event for most patients and their families. Many patients with this relatively common malignancy present at a stage of disease not amenable to cancer-directed resectional therapy, and are treated via nonoperative palliative measures, with median survival of 4-8 months post- diagnosis. Conclusion: A minority of patients present with disease limited to the pancreas and periampullary region and are candidates for resectional therapy. The prognosis for these patients is determined by several factors: clinicopathologic staging, tumor biology and molecular genetics, perioperative factors and the use of postoperative adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)129-133
Number of pages5
JournalLangenbeck's Archives of Surgery
Volume383
Issue number2
StatePublished - Apr 1998

Fingerprint

Pancreatic Neoplasms
Neoplasm Staging
Molecular Biology
Pancreas
Neoplasms
Adenocarcinoma
Therapeutics
Survival

Keywords

  • Adjuvant chemoradiation therapy
  • p53 tumor suppressor gene
  • Pancreatic adenocarcinoma
  • Tumor DNA content

ASJC Scopus subject areas

  • Surgery

Cite this

Prognostic factors in ductal pancreatic cancer. / Yeo, C. J.; Cameron, John L.

In: Langenbeck's Archives of Surgery, Vol. 383, No. 2, 04.1998, p. 129-133.

Research output: Contribution to journalArticle

@article{83b5597811b841429d39832ad87d9b2c,
title = "Prognostic factors in ductal pancreatic cancer",
abstract = "Introduction: The diagnosis of pancreatic adenocarcinoma remains a devastating life event for most patients and their families. Many patients with this relatively common malignancy present at a stage of disease not amenable to cancer-directed resectional therapy, and are treated via nonoperative palliative measures, with median survival of 4-8 months post- diagnosis. Conclusion: A minority of patients present with disease limited to the pancreas and periampullary region and are candidates for resectional therapy. The prognosis for these patients is determined by several factors: clinicopathologic staging, tumor biology and molecular genetics, perioperative factors and the use of postoperative adjuvant therapy.",
keywords = "Adjuvant chemoradiation therapy, p53 tumor suppressor gene, Pancreatic adenocarcinoma, Tumor DNA content",
author = "Yeo, {C. J.} and Cameron, {John L}",
year = "1998",
month = "4",
language = "English (US)",
volume = "383",
pages = "129--133",
journal = "Langenbeck's Archives of Surgery",
issn = "1435-2443",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Prognostic factors in ductal pancreatic cancer

AU - Yeo, C. J.

AU - Cameron, John L

PY - 1998/4

Y1 - 1998/4

N2 - Introduction: The diagnosis of pancreatic adenocarcinoma remains a devastating life event for most patients and their families. Many patients with this relatively common malignancy present at a stage of disease not amenable to cancer-directed resectional therapy, and are treated via nonoperative palliative measures, with median survival of 4-8 months post- diagnosis. Conclusion: A minority of patients present with disease limited to the pancreas and periampullary region and are candidates for resectional therapy. The prognosis for these patients is determined by several factors: clinicopathologic staging, tumor biology and molecular genetics, perioperative factors and the use of postoperative adjuvant therapy.

AB - Introduction: The diagnosis of pancreatic adenocarcinoma remains a devastating life event for most patients and their families. Many patients with this relatively common malignancy present at a stage of disease not amenable to cancer-directed resectional therapy, and are treated via nonoperative palliative measures, with median survival of 4-8 months post- diagnosis. Conclusion: A minority of patients present with disease limited to the pancreas and periampullary region and are candidates for resectional therapy. The prognosis for these patients is determined by several factors: clinicopathologic staging, tumor biology and molecular genetics, perioperative factors and the use of postoperative adjuvant therapy.

KW - Adjuvant chemoradiation therapy

KW - p53 tumor suppressor gene

KW - Pancreatic adenocarcinoma

KW - Tumor DNA content

UR - http://www.scopus.com/inward/record.url?scp=0031665514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031665514&partnerID=8YFLogxK

M3 - Article

C2 - 9641885

AN - SCOPUS:0031665514

VL - 383

SP - 129

EP - 133

JO - Langenbeck's Archives of Surgery

JF - Langenbeck's Archives of Surgery

SN - 1435-2443

IS - 2

ER -